| May 22, 2014 | ISSUE NUMBER 352 VOL 4 |
|
Opinion
The Future of Cancer Care?
In the next 3–5 years, innovation in cancer care will not be about the technology or some great pharmaceutical breakthrough. It will really be about changes in human behavior, writes Jim Austin ...Read more
Event
Paying for the Future of Medicine
Panelists at The Atlantic's “Future of Medicine” conference wondered if the hallmark of innovation is in fact higher drug prices. Ben Comer reports
...Read more
Rymax Marketing Services is a one-stop shop for medical meetings and event planners offering unique experiences and services. We create sales incentive and loyalty programs designed to increase employee and customer retention. With 300 aspirational, high equity brands and exclusive rewards to compliment signature events, we ship directly from our nationwide warehouses to help drive our clients’ ROI and revenue. www.rymaxinc.com/customer-loyalty.aspx
Europe
Rebuilding the Competitive Agenda
Partly because of the tougher conditions they face, and partly because shifts in ownership and in corporate strategy, the European Federation of Pharmaceutical Industries and Associations and the European Generics Association have started to work together much more closely
...Read more
Adam Smith Conferences’ Russian Pharmaceutical Forum
Fresh and innovative programme offers plenty of topics and themes to stimulate lively and constructive discussions. HEARover 100 expert speakers (Novartis, AstraZeneca, Pfizer, Teva, Stada, Takeda, Dr.Reddys), EXPERIENCE sessions sharing the best pharmaceutical practices (Generics vs Brands, Biogeneric Producers vs Biological Innovators, Patient Advocacy), LISTEN to special guest addresses (Multichannel Marketing Strategy) and GATHER inspirational ideas from executive debates (Distribution Strategy).
Date: June 17 - 19, 2014
Location: St.Petersburg, Russia
Venue: Corinthia St.Petersburg Hotel
Contact: Lyudmyla Durneva
+44 (0) 207 551 9065
Lyudmyla@adamsmithconferences.com
Website: www.adamsmithconferences.com/as2279PHEX
Regulatory
FDA Takes First Amendment Issues “Seriously”
Several legal cases have challenged the Food and Drug Administration’s approach to regulating industry communications about medical products, and agency officials now are acknowledging the importance of addressing these developments head-on ...Read more
How Digital Medicine Can Pinpoint Dosing Regimens to Optimize Drug Efficacy and Safety
On Demand Webcast
To Register free:
 www.pharmexec.com/pinpoint
Vaccines
Vaccine Demand Spurs Innovation
Vaccine development is on a roll, boosted by biomedical research uncovering new molecular targets for preventives and treatments, as well as innovative techniques for enhancing vaccine potency and production. Jill Wechsler reports ...Read more
|
|
|
|
 //Cour Pharmaceutical Development Company (Chicago, IL) announced the election of Catherine J. Mackey, Ph.D., as Chairman of its Board of Directors.//Clarus Therapeutics, Inc. (Northbrook, IL) appointed Patrick Shea as Chief Commercial Officer.//Dr Mark Velleca became the new CEO of G1 Therapeutics (Research Triangle Park, NC).//Jazz Pharmaceuticals (Dublin, Ireland) named Russell J. Cox as Chief Operating Officer.//Industry veteran Linda C. Bain joined Avalanche Biotechnologies (Melno Park, CA) as Chief Financial Officer.//ACM Global Central Laboratory (Rochester, NY) appointed Richard Cunningham as Director of Global Logistics.//The Chairman and CEO of NeoStem, Inc. (New York, NY) Robin L. Smith, has been a selected as a finalist for 2014 in the New York region for the EY Entrepreneur of the Year Award.// |
|
|
|
|
|
 |
|
|
| |
 |
|
 |
|
 |
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
|
|
|
|
